A detailed history of Alpine Associates Management Inc. transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Alpine Associates Management Inc. holds 2,353,694 shares of CERE stock, worth $0. This represents 4.62% of its overall portfolio holdings.

Number of Shares
2,353,694
Previous 2,341,394 0.53%
Holding current value
$0
Previous $99 Million 2.76%
% of portfolio
4.62%
Previous 3.86%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$38.96 - $42.75 $479,208 - $525,825
12,300 Added 0.53%
2,353,694 $96.2 Million
Q1 2024

May 09, 2024

BUY
$40.88 - $43.27 $28.5 Million - $30.2 Million
697,294 Added 42.41%
2,341,394 $99 Million
Q4 2023

Feb 07, 2024

BUY
$20.27 - $42.44 $33.3 Million - $69.8 Million
1,644,100 New
1,644,100 $69.7 Million

Others Institutions Holding CERE

About Cerevel Therapeutics Holdings, Inc.


  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Alpine Associates Management Inc. Portfolio

Follow Alpine Associates Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpine Associates Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Alpine Associates Management Inc. with notifications on news.